May 18, 2020 / 08:00PM GMT
Presentation
May 18, 2020 / 08:00PM GMT
=====================
Corporate Participants
=====================
* Samantha Budd Haeberlein
Biogen Inc. - VP of Clinical Development
=====================
Samantha Budd Haeberlein - Biogen Inc. - VP of Clinical Development
Hello. My name is Samantha Budd Haeberlein. And on behalf of the authors listed here, I'm going to take you through a presentation of EMERGE and ENGAGE topline result, which were 2 Phase III studies to evaluate aducanumab in patients with early Alzheimer's disease.
This presentation may include forward-looking statements.
The aducanumab Phase III studies called EMERGE and ENGAGE were 2 identical 18-month duration, randomized, double-blind, placebo-controlled Phase III studies. They enrolled 3,285 patients at 348 sites in 20 countries which are listed to the right. The population study were early Alzheimer's disease, which included subjects with MCI due to Alzheimer's disease and mild Alzheimer's disease dementia.
There were 2 dosing regimens, a low and a high dosing
Biogen Inc to Discuss Aducanumab Phase 3 Topline Results at AAN Presentation Transcript
May 19, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers